+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biologic Medications for Psoriasis Market by Drug Class, Route Of Administration, Distribution Channel, Patient Age Group - Global Forecast to 2030- Product Image
Biologic Medications for Psoriasis Market by Drug Class, Route Of Administration, Distribution Channel, Patient Age Group - Global Forecast to 2030- Product Image
Sale

Biologic Medications for Psoriasis Market by Drug Class, Route Of Administration, Distribution Channel, Patient Age Group - Global Forecast to 2030

  • PDF Icon

    Report

  • 198 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6079387
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Navigating the Evolving Terrain of Psoriasis Biologic Therapies

The therapeutic landscape for psoriasis has undergone a profound transformation with the advent of biologic medications, offering targeted mechanisms of action that have revolutionized patient care. Early life cycles of traditional systemic therapies gave way to precision-driven biologics that inhibit specific inflammatory pathways. As a result, clinicians and payers alike have welcomed these advances, driving accelerated adoption and enabling patients to achieve higher rates of skin clearance with sustained safety profiles.

This executive summary distills the latest market research on biologic psoriasis treatments, shedding light on the forces reshaping the industry. It captures major shifts in drug classes, assesses the ripple effects of 2025 tariff changes, and unpacks critical segmentation, regional, and competitive insights. Through a structured analysis, stakeholders will gain clarity on emergent opportunities and strategic imperatives needed to thrive in this dynamic environment.

Emerging Paradigm Shifts Driving Psoriasis Treatment

Recent years have witnessed a seismic shift in psoriasis treatment paradigms, propelled by targeted cytokine inhibitors that offer unprecedented efficacy and safety. Interleukin 12/23, 17, and 23 inhibitors have redefined clinical outcomes, outpacing conventional therapies and heralding a new era of personalized medicine. The entry of tumor necrosis factor alpha inhibitors further diversified the armamentarium, enabling clinicians to tailor regimens based on patient comorbidities and response profiles.

Moreover, innovations in formulation and delivery have augmented patient convenience and adherence. Subcutaneous injections now dominate clinic and at-home administration, reducing infusion center burdens while enhancing the patient experience. At the same time, advancements in manufacturing and supply chain resilience have enabled manufacturers to maintain steady product availability even amidst tightening trade regulations.

As these breakthroughs converge, the psoriasis biologics market is experiencing accelerated fragmentation, with emerging molecules carving out niches based on speed of onset, durability of response, and safety in special populations. This transformative landscape demands that stakeholders stay ahead of scientific trends and delivery innovations to maintain competitive advantage.

Assessing the 2025 US Tariffs' Ripple Effect on Biologic Supply Chains

The implementation of new United States tariffs in 2025 has sent ripples through the global biologic supply chain, altering cost structures and pricing dynamics. Active pharmaceutical ingredients and key biologic components imported from select regions now face increased duties, compelling manufacturers to reassess sourcing strategies. These changes have triggered downstream adjustments in list prices and contractual terms with payers and providers.

In response, global and regional suppliers have explored cost offset measures such as localized manufacturing partnerships, renegotiated freight contracts, and strategic inventory positioning. While some players have absorbed a portion of the tariff burden to protect market share, others have passed incremental costs onto customers through tiered pricing models. This dichotomy underscores the importance of agile commercial and operational planning to mitigate margin erosion.

The 2025 tariff landscape also underscores the value of diversified distribution channels. Manufacturers leveraging a blend of hospital, retail, and specialty pharmacies have demonstrated greater resilience against supply disruptions. As the market adapts, continuous monitoring of regulatory adjustments will be essential to ensure pricing strategies remain compliant and competitive.

Deep-Dive into Market Segmentation Reveals Nuanced Demand Drivers

A detailed examination of market segmentation reveals differentiated growth drivers across drug classes, administration routes, distribution channels, and patient demographics. Within the realm of drug classes, interleukin 12/23 inhibitors such as ustekinumab continue to command significant market share due to their established efficacy. Meanwhile, interleukin 17 inhibitors, including brodalumab, ixekizumab, and secukinumab, have gained traction for their rapid onset of action. Interleukin 23 inhibitors-guselkumab, risankizumab, and tildrakizumab-are carving out strong positions by offering durable response with potentially fewer dosing events. Tumor necrosis factor alpha inhibitors, led by adalimumab, etanercept, and infliximab, remain mainstays in certain therapeutic protocols, especially where longer clinical experience underpins prescribing confidence.

In terms of administration, the market divides between intravenous infusion and subcutaneous injection, each presenting unique considerations. Intravenous infusions allow precise dosing in controlled settings, which appeals to providers managing complex comorbidities. Subcutaneous injections, on the other hand, empower patients with at-home convenience and reduced clinic visits, stimulating higher adoption among self-administered therapies.

Distribution channels further influence accessibility and pricing. Hospital pharmacies offer streamlined formulary inclusion, while retail pharmacies provide broad patient reach. Specialty pharmacies excel in managing complex biologic therapies, offering tailored patient support programs that drive adherence. Finally, segmenting by patient age group highlights distinct needs between adult and pediatric populations. Adults represent the bulk of demand with steady uptake of established biologics, whereas pediatric patients are driving accelerated research and labeling expansions, signaling a growing opportunity in younger cohorts.

Regional Dynamics Shaping Biologic Adoption Across Major Markets

Regional market dynamics underscore the varying pace of biologic adoption and commercialization strategies. In the Americas, robust payer frameworks and high per-capita healthcare spending have fostered widespread uptake of premium biologic therapies. The United States leads in volume and revenue, buoyed by favorable reimbursement policies and an extensive network of specialist physicians.

Across Europe, the Middle East, and Africa, heterogeneity in regulatory pathways and reimbursement criteria shape market entry strategies. Western Europe exhibits mature demand, with cost-effectiveness analyses guiding formulary decisions, while emerging markets in Eastern Europe and the Middle East prioritize volume-based procurement. In Africa, limited infrastructure and variable access present ongoing challenges, yet targeted partnerships and local distribution agreements are gradually expanding reach.

In the Asia-Pacific region, rising incidence rates, improving healthcare infrastructure, and evolving insurance schemes create fertile ground for biologic growth. Markets such as Japan and Australia demonstrate early adoption of innovative therapies, whereas China and India offer immense scale potential, contingent on local pricing agreements and production partnerships that align with regional affordability thresholds.

Competitive Landscape Highlights Strategic Positioning of Biologic Innovators

The competitive landscape is anchored by a handful of established pharmaceutical leaders and emerging innovators. Market incumbents with broad portfolios benefit from integrated commercial networks and proven manufacturing capabilities. Companies with flagship biologics like adalimumab and ustekinumab leverage brand recognition and comprehensive patient support services to sustain market dominance.

Concurrently, next-generation entrants are capturing share by differentiating on novel interleukin targets and optimized dosing regimens. Strategic alliances between large pharmaceutical corporations and specialty biotech firms are facilitating rapid scale-up of promising candidates. These partnerships, along with targeted acquisitions, are reshaping the competitive hierarchy as companies vie to secure late-stage pipeline assets and fortify geographic presence.

Strategic Imperatives for Stakeholders to Navigate Evolving Markets

To capitalize on the shifting market dynamics, industry leaders should prioritize integrated supply chain resilience. Establishing regional manufacturing hubs and diversified sourcing agreements will be critical to buffering against regulatory and tariff volatility. Simultaneously, investing in patient-centric delivery technologies, such as prefilled subcutaneous devices, will enhance adherence and broaden therapeutic accessibility.

Moreover, companies should deepen collaborations with payers and healthcare providers to align on value-based contracting models. Demonstrating real-world effectiveness and long-term cost savings through patient registries and health economics analyses will be instrumental in securing favorable formulary placements. Finally, targeted pediatric research initiatives can unlock underserved patient segments and drive early adoption in the next generation of psoriasis therapy recipients.

Robust Methodological Framework Ensuring Data Integrity and Insight Validity

This report’s findings are underpinned by a robust methodological framework that integrates both primary and secondary research. Secondary sources included peer-reviewed journals, regulatory filings, and proprietary databases. These were complemented by qualitative insights from in-depth interviews with key opinion leaders, market access specialists, and supply chain executives across major regions.

Quantitative analyses leveraged prescription data, shipment volumes, and financial disclosures to validate market trends and segmentation dynamics. Rigorous triangulation methods ensured data consistency, while expert review panels provided validation and contextual refinement. This comprehensive approach guarantees that the insights presented are both reliable and actionable for strategic decision-making.

Synthesis of Findings Illuminates Path Forward in Psoriasis Biologics

The convergence of targeted cytokine inhibition, evolving delivery modalities, and regulatory headwinds has created a complex yet opportunity-rich landscape for psoriasis biologics. By dissecting segmentation drivers, regional differences, and competitive strategies, this summary illuminates the critical levers shaping market trajectories. Stakeholders equipped with these insights are better positioned to anticipate disruptions and harness growth pockets within established and emerging geographies.

Looking ahead, sustained innovation in interleukin targeting and patient support mechanisms will define the next phase of industry advancement. Aligning commercial, operational, and clinical priorities will be essential to unlock maximum value in a market characterized by rapid change and intense competition.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Drug Class
    • Interleukin 12/23 Inhibitors
      • Ustekinumab
    • Interleukin 17 Inhibitors
      • Brodalumab
      • Ixekizumab
      • Secukinumab
    • Interleukin 23 Inhibitors
      • Guselkumab
      • Risankizumab
      • Tildrakizumab
    • Tumor Necrosis Factor Alpha Inhibitors
      • Adalimumab
      • Etanercept
      • Infliximab
  • Route Of Administration
    • Intravenous Infusion
    • Subcutaneous Injection
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Specialty Pharmacies
  • Patient Age Group
    • Adult Patients
    • Pediatric Patients
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • AbbVie Inc.
  • Novartis AG
  • Eli Lilly and Company
  • Johnson & Johnson
  • Amgen Inc.
  • UCB S.A.
  • Merck KGaA
  • Boehringer Ingelheim International GmbH
  • Celltrion, Inc.
  • Samsung Bioepis Co., Ltd.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Biologic Medications for Psoriasis Market, by Drug Class
8.1. Introduction
8.2. Interleukin 12/23 Inhibitors
8.2.1. Ustekinumab
8.3. Interleukin 17 Inhibitors
8.3.1. Brodalumab
8.3.2. Ixekizumab
8.3.3. Secukinumab
8.4. Interleukin 23 Inhibitors
8.4.1. Guselkumab
8.4.2. Risankizumab
8.4.3. Tildrakizumab
8.5. Tumor Necrosis Factor Alpha Inhibitors
8.5.1. Adalimumab
8.5.2. Etanercept
8.5.3. Infliximab
9. Biologic Medications for Psoriasis Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous Infusion
9.3. Subcutaneous Injection
10. Biologic Medications for Psoriasis Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Retail Pharmacies
10.4. Specialty Pharmacies
11. Biologic Medications for Psoriasis Market, by Patient Age Group
11.1. Introduction
11.2. Adult Patients
11.3. Pediatric Patients
12. Americas Biologic Medications for Psoriasis Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Biologic Medications for Psoriasis Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Biologic Medications for Psoriasis Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. AbbVie Inc.
15.3.2. Novartis AG
15.3.3. Eli Lilly and Company
15.3.4. Johnson & Johnson
15.3.5. Amgen Inc.
15.3.6. UCB S.A.
15.3.7. Merck KGaA
15.3.8. Boehringer Ingelheim International GmbH
15.3.9. Celltrion, Inc.
15.3.10. Samsung Bioepis Co., Ltd.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET MULTI-CURRENCY
FIGURE 2. BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET MULTI-LANGUAGE
FIGURE 3. BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY USTEKINUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY BRODALUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY IXEKIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY SECUKINUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY GUSELKUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY RISANKIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TILDRAKIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ETANERCEPT, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 53. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 54. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 55. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 56. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 57. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 58. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 60. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 61. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 62. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 63. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 64. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 65. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 66. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 67. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 68. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 94. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 95. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 96. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 102. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 103. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 104. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 105. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 106. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 107. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 110. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 111. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 112. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 113. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 114. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 115. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 116. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 126. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 127. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 128. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 129. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 130. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 131. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 132. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 133. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 134. SPAIN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 135. SPAIN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 136. SPAIN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 137. SPAIN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 138. SPAIN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 139. SPAIN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 140. SPAIN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 141. SPAIN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 143. UNITED ARAB EMIRATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 145. UNITED ARAB EMIRATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 146. UNITED ARAB EMIRATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 149. UNITED ARAB EMIRATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 150. SAUDI ARABIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 151. SAUDI ARABIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 152. SAUDI ARABIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 153. SAUDI ARABIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 154. SAUDI ARABIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 158. SOUTH AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 159. SOUTH AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 160. SOUTH AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 166. DENMARK BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 167. DENMARK BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 168. DENMARK BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 169. DENMARK BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 170. DENMARK BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 171. DENMARK BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. DENMARK BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 173. DENMARK BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 174. NETHERLANDS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 175. NETHERLANDS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 176. NETHERLANDS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 177. NETHERLANDS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 178. NETHERLANDS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 179. NETHERLANDS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. NETHERLANDS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. NETHERLANDS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 182. QATAR BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 183. QATAR BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 184. QATAR BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 185. QATAR BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 186. QATAR BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 187. QATAR BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 188. QATAR BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 189. QATAR BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 190. FINLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 191. FINLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 192. FINLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 193. FINLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 194. FINLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 195. FINLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. FINLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. FINLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 198. SWEDEN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 199. SWEDEN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 200. SWEDEN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 201. SWEDEN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 202. SWEDEN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 203. SWEDEN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. SWEDEN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 205. SWEDEN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 206. NIGERIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 214. EGYPT BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 215. EGYPT BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 216. EGYPT BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 217. EGYPT BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 218. EGYPT BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 219. EGYPT BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. EGYPT BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 221. EGYPT BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 222. TURKEY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 223. TURKEY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 224. TURKEY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 225. TURKEY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 226. TURKEY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 227. TURKEY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 228. TURKEY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 229. TURKEY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 230. ISRAEL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 231. ISRAEL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 232. ISRAEL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 233. ISRAEL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 234. ISRAEL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 235. ISRAEL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 236. ISRAEL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 237. ISRAEL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 238. NORWAY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 239. NORWAY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 240. NORWAY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 241. NORWAY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 242. NORWAY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 243. NORWAY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. NORWAY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 245. NORWAY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 246. POLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 247. POLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 248. POLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 249. POLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 250. POLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 251. POLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 252. POLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 253. POLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 254. SWITZERLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 255. SWITZERLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 256. SWITZERLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 262. ASIA-PACIFIC BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 263. ASIA-PACIFIC BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 264. ASIA-PACIFIC BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 265. ASIA-PACIFIC BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 266. ASIA-PACIFIC BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 270. ASIA-PACIFIC BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 271. CHINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 272. CHINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 273. CHINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 274. CHINA BIOLOGIC M

Companies Mentioned

The companies profiled in this Biologic Medications for Psoriasis market report include:
  • AbbVie Inc.
  • Novartis AG
  • Eli Lilly and Company
  • Johnson & Johnson
  • Amgen Inc.
  • UCB S.A.
  • Merck KGaA
  • Boehringer Ingelheim International GmbH
  • Celltrion, Inc.
  • Samsung Bioepis Co., Ltd.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Psoriasis Therapeutics Market by Therapeutic Class, Route of Administration, Distribution Channel, End User, Disease Severity, Patient Age Group - Global Forecast to 2030 - Product Image

Psoriasis Therapeutics Market by Therapeutic Class, Route of Administration, Distribution Channel, End User, Disease Severity, Patient Age Group - Global Forecast to 2030

  • Report
  • 187 Pages
  • Global
From
Psoriasis Drugs Market by Drug Class, Route of Administration, Distribution Channel, Patient Severity - Global Forecast to 2030 - Product Image

Psoriasis Drugs Market by Drug Class, Route of Administration, Distribution Channel, Patient Severity - Global Forecast to 2030

  • Report
  • 197 Pages
  • Global
From
Psoriasis Treatment - Global Strategic Business Report - Product Image

Psoriasis Treatment - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Chronic Plaque Psoriasis Market Report 2025 - Product Image

Chronic Plaque Psoriasis Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Psoriasis Treatment Market Report and Forecast 2024-2032 - Product Image

Psoriasis Treatment Market Report and Forecast 2024-2032

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.